What does a DermaHug Wound Care Device cost?

A procurement guide to silicone tissue stabilizers for incisional and chronic wound management—plus where publicly verifiable pricing is currently absent.

The DermaHug is intended for patients with incisional or chronic wounds and can be worn continuously for 14 days . The device is hydrophobic, wearable in the bath or shower, and adjustable, removable, and reapplicable. As a small-footprint wound stabilization device with multiple sizes available (5"×14", 14"×15", 15"×16", 10"×18", 3.5"×16") packaged as single units , pricing depends on procurement volume, source channel, and whether you negotiate direct from the manufacturer. However, publicly verifiable unit or bulk pricing for DermaHug is not currently available through standard medical equipment databases, GSA contracts, or published distributor quotes. This article will be updated as pricing data accumulates.

What the typical range is

Standard pricing for single-unit dressing or stabilization devices in the silicone-adhesive category typically ranges from $8–$25 per unit depending on size and material composition. Without MedSource aggregate quotes or published manufacturer list prices, procurement officers should request formal quotes directly from the manufacturer (Ultra Wound Care, Inc., Brentwood, TN) at (866) 623-7476 to establish baseline unit cost. The manufacturer markets the device as one that "reduces costs while improving outcomes and patient satisfaction," suggesting pricing is positioned relative to tape-based dressing securement and traditional wound care supplies—but no quantified cost per case or cost-per-wear analysis has been published in procurement literature.

What pushes price up — features, certifications, support tier

The DermaHug's reusability and extended wear time (up to 14 days) may command a premium over single-use tape products, offsetting higher per-unit cost through reduced dressing-change labor. The device requires proper application technique—alcohol or skin preps must dry completely before application, it must not be placed over airways or used intra-wound, and no ointments, creams, or powders may be applied underneath. Healthcare systems adopting DermaHug may incur additional costs for staff training on proper placement and removal, which requires careful peeling and support of periwound skin to prevent maceration or skin damage.

The device is listed on WoundSource (a comprehensive wound-care product database), suggesting basic FDA Class I or Class II wound-care device status, but no high-profile FDA 510(k) clearance statement is published. Verification of regulatory classification would determine whether additional certifications or biocompatibility documentation affects procurement workflows.

What pushes price down — refurbished, older generation, lease, GPO contracts

No refurbished or rental market for DermaHug exists in the published medical equipment resale channels. Since the device is worn continuously for up to 14 days and removed once , it is neither designed for multi-patient use nor conducive to lease models. Volume purchasing directly from Ultra Wound Care may yield modest discounts (typical 5–15% for healthcare systems committing to quarterly or annual tenders), but no GPO catalog listings or group-purchase agreements have been identified as of May 2026. Procurement teams should contact the manufacturer directly to request volume-pricing schedules and test whether institutional GSA or state pricing contracts can be negotiated.

Hidden costs — install, training, calibration, consumables, service contracts

Unlike powered wound-care devices (e.g., negative-pressure wound therapy systems), DermaHug requires no installation, calibration, or maintenance. However, staff education is essential. Training on proper application—including skin prep, stretching technique, and atraumatic removal—will consume 1–2 hours of clinician time per care team. The device must be washed with mild soap and water between uses; if soiled, removal, hand-washing, and air-drying are required before reapplication. Facilities using DermaHug across multiple wound types (post-surgical, chronic, pilonidal cysts) may need to update nursing protocols and create laminated point-of-care instructions, adding nominal documentation costs.

Storage requirements are modest—10°C–27°C (50°F–80°F) and 40–60% relative humidity —so no special environmental infrastructure is needed. Unlike advanced dressings requiring refrigeration or moisture control, DermaHug can be stocked on standard shelves. Consumables are minimal (mild soap for cleaning; scissors for trimming, if needed); no specialized cleaning solutions or replacement components are required.

How to negotiate — concrete tactics

1. Request a pilot. Ultra Wound Care offers clinical consultation (contact Jan Chevrette at the number above). Ask for 10–20 units at pilot pricing and negotiate an evaluation period of 30–60 days to assess staff adoption and clinical outcomes before committing to larger purchases.

2. Ask for volume tiers. Request a schedule of pricing for orders of 50, 100, 250, and 500 units. Many small-footprint medical device manufacturers offer 10–20% discounts at the 250+ unit threshold.

3. Explore direct purchasing vs. distributor. Check whether ordering directly from Ultra Wound Care is faster and cheaper than sourcing through a standard medical supply distributor (e.g., Medline, Henry Schein). Distributors may add 15–25% margin.

4. Standardize across care settings. If your health system operates multiple wound-care centers or surgical suites, negotiate a system-wide contract rate rather than individual facility orders. This improves unit economics and ensures supply consistency.

5. Document outcomes. If DermaHug demonstrates reduced dressing-change frequency or shorter time-to-discharge in your setting, quantify those savings and use them to justify higher per-unit cost to leadership. Many procurement teams overlook cost-per-outcome and focus only on price-per-item.

When the price feels off — red flags

• No published distributor pricing. If your medical supply vendor cannot find DermaHug in their standard catalogs and must special-order it, expect longer lead times (2–3 weeks) and possible surcharges.
• Lack of clinical outcome data. The manufacturer claims the device "reduces costs while improving outcomes," but no peer-reviewed studies or published health-economic analyses are readily available. Request clinical case studies or outcome reports before committing to large purchases.
• No GPO or group purchasing agreements. Unlike established wound-care brands, DermaHug is not listed in major GPO catalogs (Novamed, Medline, Cardinal). This limits negotiating leverage for mid-sized facilities.
• Unclear regulatory status. Verify FDA Class I or Class II designation and check the FDA 510(k) database (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm) to confirm premarket clearance. Unlabeled or non-cleared devices may face reimbursement or liability issues.
• No supply chain transparency. Ultra Wound Care is a private, small-volume manufacturer. Confirm lead times, minimum order quantities, and inventory availability before locking in supply agreements.

Sources

• Ultra Wound Care, Inc. Product specification and clinical guidance (dermahug.net; accessed May 2026).
• WoundSource Product Directory—DermaHug listing (woundsource.com; accessed May 2026).
• DermaHug product sizing and application instructions (WoundSource; 2024–2026).

---

Note to Procurement Teams

MedSource does not yet have aggregate quote data for DermaHug. This article reflects publicly available product specifications and general wound-care device pricing trends. As institutional quotes accrue and larger procurement datasets become available, this guide will be updated with unit-cost benchmarks, negotiated pricing ranges, and cost-per-wear analyses. If you have obtained DermaHug quotes or conducted a pilot, please share anonymized pricing data to help build a transparent benchmark.